Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
Date:9/4/2007

CALGARY, Sept. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus." The claims describe a method of using reovirus to prevent Ras-activated cancers from developing drug resistance to chemotherapeutic agents.

"Recent research conducted by the U.S. National Cancer Institute (NCI) and Cornell University demonstrated that administering reovirus in combination with various chemotherapeutic agents potentiates, or enhances tumour-killing, thus preventing the cancer cells from developing drug resistance," said Dr. Matt Coffey, Chief Scientific Officer. "This patent complements the combination REOLYSIN(R) and chemotherapy clinical program that we are pursuing in the U.K."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... IAC Industries wants to share with you the success story ... up and furnish a research lab knowing that the company ... time. How does a company make choices in lab furnishing ... efficient and cost-effective? , The solution was the versatile ... at DisperSol determined that the concept of modular lab furniture ...
(Date:5/16/2013)... ISPE announced today ... to the newly created position of Vice President ... will be responsible for stimulating ISPE’s revenue growth ... the Society’s Member-led and staff-driven business model, initiating ... organizational, membership and product marketing. , “Barbara joins ...
(Date:5/16/2013)... A new selection of laboratory ... is designed to meet the dynamic needs of ... new Cole-Parmer® MS-3400 Centrifuges are clinical ... They ensure a powerful and complete separation of ... standard four-place swinging buckets hold 50-mL tubes. With ...
(Date:5/16/2013)... May 16, 2013  HealthSparq, a trusted provider ... nation,s largest regional health plans, will debut a ... Plans (AHIP) Institute 2013 conference on June 13. ... showing how health insurance companies across the country ... and marketplace demands for increased healthcare transparency. ...
Breaking Biology Technology:New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... sizes and shapes, scientists now understand how they lose ... weighing any single atom. Such ultrasensitive measurements could ... and diagnostics, enabling the detection of minuscule disease-causing agents ... level. Researchers are interested in nanosized materials because ...
... ... , ... CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce ... a high performance ethanol fuel for cars. The first installation of the E-Fuel ...
... , , , ... Calif. and LONDON, July 27 Amgen (Nasdaq: AMGN ... companies will share commercialization of Amgen,s monoclonal antibody denosumab for postmenopausal ... product is approved in these countries. Amgen will commercialize the ...
Cached Biology Technology:1 nano-step closer to weighing a single atom 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7
(Date:5/17/2013)... Bethesda, MD (May 18, 2013) The AGA Research ... research into the relationship between the gut microbiota, one ... health and disease. , The AGA Research Awards ... colleagues from Massachusetts General Hospital and Harvard Medical School, ... Award recipient. Dr. Chan will receive $25,000 of funding, ...
(Date:5/17/2013)... residents of all ages will celebrate the science ... on our daily lives during the inaugural Atlanta ... and educators from local museums, corporations, K-12 schools ... 40 different events for children and adults at ... http://atlantasciencefestival.org . , The annual Atlanta Science ...
(Date:5/17/2013)... The iCargo project (Intelligent Cargo in Efficient and Sustainable ... thanks to an improvement in the efficiency of intermodal ... assist decision making. It comprises 29 European organisations with ... management. It has a budget totalling 17,000,000 and a ... is working to specify and develop the semantic components ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2
... Drinking water during a long-distance race may do serious ... you're drinking too much, according to a cardiologist at ... athletes who drink too much water during a race ... condition marked by a loss in the body's sodium ...
... vaccines developed by computer may sound unnerving but the ... new vaccines could bring new products onto the market ... pounds. , Researchers using informatics and computer modelling can ... in the wealth of DNA and protein sequences that ...
... a database with the necessary infrastructure to curate, ... data and protocols for an emerging model organism, ... Daphnia's ecological merit is unequaled among metazoans, largely ... and over 200 years of biological investigations. By ...
Cached Biology News:Bush, Cheney and Rumsfeld are now species of slime-mold beetles -- but strictly in homage 2Designing vaccines by computer 2
... ZMD.471. Immunogen: Synthetic peptide derived ... mouse junctophilin-1. Specificity: Specific for ... (positive controls: mouse brain and skeletal ... skeletal muscle tissues). Applications: Western ...
Request Info...
Laminin beta-1/gamma-1 (612C10)...
HSV 1 IgM...
Biology Products: